CD44 and glioblastoma: ALDH1A1 specifically catalyzes the oxidation of retinaldehyde to retinoic acid, and the latter was shown as an effective treatment against GBM cells by inducing their differentiation, reducing the expression of stem cell markers like CD133, CD44, and Sox-2, and decreasing the neurosphere-forming capacity [50].